ARTICLE | Company News
Genetic Technologies, Perlegen deal
April 26, 2010 7:00 AM UTC
Genetic Technologies said it acquired essentially all of Perlegen's assets, including all rights related to Perlegen's BREVAGen breast cancer stratification test and a suite of international patents valid until 2022 related to genomic mapping and genetic analysis. Financial terms were not disclosed.
Genetic Technologies said it plans to launch BREVAGen in the U.S. and Australia next half. The price of the test will be US$450-US$550. The test combines a DNA-based profile of breast cancer-associated SNPs with the patient's clinical history to determine the patient's lifetime and five-year risk for developing the disease. ...